Safety and efficacy of CD37-targeting Naratuximab Emtansine plus Rituximab in diffuse large B-Cell lymphoma and other non-Hodgkin's B-Cell lymphomas - A phase 2 Study

Yair Levy Moshe;Grudeva-Popova Zhanet;Trneny Marek;Jurczak Wojciech;André, Marc;et.al.
(2021) 26th European Hematology Association Congress EHA 2021 — Location: Vienna, Austria (10.June.2021)

Files

YairLevyMEHA2021.pdf
  • Open Access
  • Adobe PDF
  • 270.31 KB
Download
YairLevyMEHA2021poster.pdf
  • Open Access
  • Adobe PDF
  • 1.44 MB
Download

Details

Authors
  • Yair Levy Moshe
    Author
  • Grudeva-Popova Zhanet
    Author
  • Trneny Marek
    Author
  • Jurczak Wojciech
    Author
  • André, MarcUCLouvain
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Yair Levy Moshe, Grudeva-Popova Zhanet, Trneny Marek, Jurczak Wojciech, Pylypenko Halyna, Jagadeesh Deepa, & André, M. (2021). Safety and efficacy of CD37-targeting Naratuximab Emtansine plus Rituximab in diffuse large B-Cell lymphoma and other non-Hodgkin’s B-Cell lymphomas - A phase 2 Study. 26th European Hematology Association Congress EHA 2021, Vienna, Austria.